Yahoo Finance • 6 months ago

Verrica Pharmaceuticals Announces Presentation at the Jefferies Global Healthcare Conference in London

WEST CHESTER, Pa., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, t... Full story

Yahoo Finance • 7 months ago

Verrica Pharmaceuticals Reports Third Quarter 2023 Financial Results

– Strong awareness and interest in prescribing YCANTH™ among dermatologists and pediatricians – – Over 112 million lives covered to date on commercial insurance and managed Medicaid plans – – Conference Call Scheduled for Today at 8:30 a... Full story

Yahoo Finance • 7 months ago

Verrica Pharmaceuticals to Provide a Corporate Update and Report Third Quarter Financial Results on November 9, 2023

WEST CHESTER, Pa., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, t... Full story

Yahoo Finance • 8 months ago

Verrica Pharmaceuticals to Host Virtual KOL Event Discussing the Approval of YCANTH™ (Cantharidin) Topical Solution for the Treatment of Molluscum on October 11, 2023

WEST CHESTER, Pa., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions,... Full story

Yahoo Finance • 9 months ago

Verrica Pharmaceuticals Announces First Sale of YCANTH™ to FFF Enterprises

YCANTH™ is the first and only FDA-approved treatment for molluscum, a highly contagious viral skin infection affecting approximately 6 million people annually in the United States, primarily children FFF Enterprises is Verrica’s exclusive... Full story

Yahoo Finance • 9 months ago

Verrica Issues Statement in Support of FDA’s Warning Letters to Manufacturers and Retailers for Producing and Selling Unapproved Products for the Treatment of Molluscum Contagiosum

Verrica’s product YCANTH™ is the first and only FDA-approved treatment for molluscum, a highly contagious viral skin infection affecting approximately 6 million people annually in the United States, primarily children YCANTH™ is expected... Full story

Yahoo Finance • a year ago

Verrica Pharmaceuticals Reports First Quarter 2023 Financial Results

New Drug Application for YCANTH™ (VP-102) PDUFA Goal Date of July 23, 2023 - Potential to Become Only FDA-approved Therapy for Treatment of Molluscum Contagiosum Raised Gross Proceeds of $32.5 Million in February 2023 in an Underwritten O... Full story

Yahoo Finance • a year ago

Verrica Pharmaceuticals Announces Dosing of the First Patient in Part 2 of Phase 2 Study Evaluating VP-315 for the Treatment of Basal Cell Carcinoma

WEST CHESTER, Pa., April 12, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or, the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions,... Full story

Yahoo Finance • a year ago

Verrica Pharmaceuticals Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference

WEST CHESTER, Pa., April 11, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced T... Full story

Yahoo Finance • a year ago

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results

New Drug Application for VP-102 assigned PDUFA goal date of July 23, 2023 VP-102 has potential to address the approximately six million patients in the U.S. with molluscum contagiosum Dosing of first patient in Part 2 of Phase 2 study of... Full story

Yahoo Finance • a year ago

Verrica Pharmaceuticals Announces Participation at The Cowen 43rd Annual Health Care Conference

WEST CHESTER, Pa., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced Te... Full story

Yahoo Finance • a year ago

Verrica Pharmaceuticals Announces FDA Acceptance of Filing of Resubmitted NDA for VP-102 for the Treatment of Molluscum Contagiosum

Assigns PDUFA goal date of July 23, 2023 VP-102 (cantharidin 0.7% Topical Solution) could potentially be the first FDA-approved treatment for molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 millio... Full story

Yahoo Finance • a year ago

Verrica Announces Pricing of $32.5 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

WEST CHESTER, Pa., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (NASDAQ: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the... Full story

Yahoo Finance • a year ago

Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum

Potential First FDA-approved Therapy for Treatment of Molluscum Contagiosum Prevalence of Over 6 Million Molluscum Contagiosum Patients in the U.S. Alone WEST CHESTER, Pa., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc.... Full story

Yahoo Finance • a year ago

Bullish insiders bet US$11m on Verrica Pharmaceuticals Inc. (NASDAQ:VRCA)

In the last year, multiple insiders have substantially increased their holdings of Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) stock, indicating that insiders' optimism about the company's prospects has increased. Although we don't think s... Full story

Yahoo Finance • 2 years ago

Verrica Pharmaceuticals Reports Third Quarter 2022 Financial Results

Reiterates expectation to resubmit NDA for VP-102 for Molluscum Contagiosum in Q1 2023 Part 1 of Phase 2 for VP-LTX-315 for Basal Cell Carcinoma on track to conclude Q1 2023 WEST CHESTER, Pa., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Verrica... Full story

Yahoo Finance • 2 years ago

Verrica Pharmaceuticals Reports Second Quarter 2022 Financial Results

Verrica held Type A meeting with the FDA regarding the path forward for the resubmission and potential approval of the NDA for VP-102 for the treatment of molluscum contagiosum Verrica has begun working with Piramal Pharma Solutions for p... Full story

Yahoo Finance • 2 years ago

VRCA FRIDAY DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Verrica Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important August 5 Deadline in Securities Class Action – VRCA

NEW YORK, Aug. 03, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) between May 28, 2021 and May 24, 2022, both dates inc... Full story

Yahoo Finance • 2 years ago

DEADLINE ALERT for APYX, VRCA, APPS, TDOC: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

BENSALEM, Pa., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the d... Full story

Mentioned:

• APPS
• APYX
• TDOC

Yahoo Finance • 2 years ago

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Teladoc, Verrica, Apyx, and Waste Management and Encourages Investors to Contact the Firm

NEW YORK, July 31, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Teladoc Health, Inc. (NYS... Full story

Mentioned:

• APYX
• TDOC
• WM